title: Quality of life of 1276 elderly patients with prostate cancer, starting treatment with a gonadotropin-releasing hormone agonist: results of a French observational study.
abstract: This French observational, longitudinal, prospective study described the health-related quality of life (HRQoL) of elderly men (≥75 years old) with prostate cancer after initiating gonadotropin-releasing hormone (GnRH) agonist therapy. At baseline and 3-6 months after baseline, European Organisation for Research and Treatment of Cancer quality of life questionnaire-core 30 (QLQ-C30) and prostate-specific (QLQ-PR25) questionnaires were completed by patients. Data from 1276 patients were analyzed. At baseline, mean (±SD) age was 80 (±4.1) years, 29.1% of patients had Gleason scores ≥8 and 24.9% had metastases. At baseline, increasing age, presence of metastasis and presence of comorbidity had a negative impact on QLQ-C30 and QLQ-PR25 scores. At follow-up, improvement in emotional-functioning (2.8; p < 0.001), social-functioning (1.7; p = 0.011), global HRQoL (1.6; p = 0.029), sleep-disturbance (-2.1; p = 0.011), appetite-loss (-4.0; p < 0.001) and pain (-4.1; p < 0.001) QLQ-C30 scores were observed. In addition, there was a worsening in treatment-related symptom (8.6; p < 0.001), sexual-activity (-5.5; p < 0.001) and sexual-functioning (-22.6; p < 0.001) QLQ-PR25 scores, and an improvement in urinary symptoms (-3.7; p < 0.001) and incontinence aid (-2.9; p = 0.023) QLQ-PR25 scores. This study shows that, apart from the expected impact on sexual functioning domains, HRQoL is not adversely affected by 3-6 months of GnRH agonist therapy in older men with prostate cancer.
authors.affiliation: Hospital Foch , Suresnes , France .
authors.forename: Thierry
authors.initials: T
authors.lastname: Lebret
authors.forename: Stéphane
authors.initials: S
authors.lastname: Culine
authors.forename: Jean-Louis
authors.initials: JL
authors.lastname: Davin
authors.forename: Christophe
authors.initials: C
authors.lastname: Hennequin
authors.forename: Jean-Pierre
authors.initials: JP
authors.lastname: Mignard
authors.forename: Jean-Luc
authors.initials: JL
authors.lastname: Moreau
authors.forename: Dominique
authors.initials: D
authors.lastname: Rossi
authors.forename: Marc
authors.initials: M
authors.lastname: Zerbib
authors.forename: Abdel
authors.initials: A
authors.lastname: Mahmoudi
authors.forename: Igor
authors.initials: I
authors.lastname: Latorzeff
mesh_terms: D000368:Aged; D000369:Aged, 80 and over; D006801:Humans; D008297:Male; D005500:Follow-Up Studies; D005602:France; D007987:Gonadotropin-Releasing Hormone / Q000819:agonists; D006304:Health Status; D011446:Prospective Studies; D011471:Prostatic Neoplasms / Q000188:drug therapy / Q000523:psychology; D011788:Quality of Life / Q000523:psychology; D011795:Surveys and Questionnaires; D016896:Treatment Outcome
chemical_list: D007987:Gonadotropin-Releasing Hormone
keywords: Elderly; GnRH agonist; prostate cancer; quality of life